Olga Martelli

Rome, 00168, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Prognostic Value of the Systemic Immune-Inflammation Index in Advanced Endometrial Cancer Treated with Pembrolizumab-Lenvatinib: A Retrospective Real-World Study.

Prognostic Value of the Systemic Immune-Inflammation Index in Advanced Endometrial Cancer Treated with Pembrolizumab-Lenvatinib: A Retrospective Real-World Study.

Journal: Current oncology (Toronto, Ont.)

Published: May 01, 2026

Endocrine toxicities in immune checkpoint inhibitors and tyrosine kinase inhibitors combined treatment: from clinical trials to real-life practice.

Endocrine toxicities in immune checkpoint inhibitors and tyrosine kinase inhibitors combined treatment: from clinical trials to real-life practice.

Journal: Endocrine

Published: December 16, 2025

Peripheral Thyroid Hormones, Inflammatory and Skeletal Muscle Indexes in Advanced Cervical Cancer Treated With Cemiplimab.

Peripheral Thyroid Hormones, Inflammatory and Skeletal Muscle Indexes in Advanced Cervical Cancer Treated With Cemiplimab.

Journal: Journal of cachexia, sarcopenia and muscle

Published: February 13, 2025

Exploratory analysis of the effect of a dexamethasone-sparing regimen for prophylaxis of cisplatin-induced emesis on food intake (LUNG-NEPA study).

Exploratory analysis of the effect of a dexamethasone-sparing regimen for prophylaxis of cisplatin-induced emesis on food intake (LUNG-NEPA study).

Journal: Scientific reports

Published: October 10, 2022

Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant/palonosetron) in the cisplatin setting: results from a randomized phase 3 study.

Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant/palonosetron) in the cisplatin setting: results from a randomized phase 3 study.

Journal: BMC cancer

Published: April 22, 2022

Detection of ALK fusion variants by RNA-based NGS and clinical outcome correlation in NSCLC patients treated with ALK-TKI sequences.

Detection of ALK fusion variants by RNA-based NGS and clinical outcome correlation in NSCLC patients treated with ALK-TKI sequences.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 28, 2022

Management of small cell lung cancer patient in the regions of Lazio, Umbria and Sardinia.

Management of small cell lung cancer patient in the regions of Lazio, Umbria and Sardinia.

Journal: Recenti progressi in medicina

Published: October 14, 2021

Dexamethasone-Sparing Regimens with Oral Netupitant and Palonosetron for the Prevention of Emesis Caused by High-Dose Cisplatin: A Randomized Noninferiority Study.

Dexamethasone-Sparing Regimens with Oral Netupitant and Palonosetron for the Prevention of Emesis Caused by High-Dose Cisplatin: A Randomized Noninferiority Study.

Journal: The oncologist

Published: February 25, 2021

Long-term outcome of pemetrexed maintenance for advanced nonsquamous non-small-cell lung cancer: a real-world observational cohort study.

Long-term outcome of pemetrexed maintenance for advanced nonsquamous non-small-cell lung cancer: a real-world observational cohort study.

Journal: Recenti progressi in medicina

Published: December 28, 2020

Molecular imaging in immuno-oncology: current status and translational perspectives.

Molecular imaging in immuno-oncology: current status and translational perspectives.

Journal: Expert review of molecular diagnostics

Published: November 20, 2020

Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab.

Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab.

Journal: Expert opinion on biological therapy

Published: February 04, 2020

Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study.

Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study.

Journal: Advances in therapy

Published: December 12, 2019

Showing 1-12 of 27

Last Updated: 09/26/2026